ironwood

(redirected from ironwoods)
Also found in: Dictionary, Thesaurus.

ironwood:

see hornbeamhornbeam
or ironwood,
name in North America for two groups of trees of the family Betulaceae (birch family), native to the eastern half of the continent. Carpinus caroliniana, also called blue beech and water beech, has smooth gray bark.
..... Click the link for more information.
.

ironwood

[′ī·ərn ‚wu̇d]
(botany)
Any of a number of hardwood trees in the United States, including the American hornbeam, the buckwheat, and the eastern hophornbeam.

ironwood

1. any of various betulaceous trees, such as hornbeam, that have very hard wood
2. a Californian rosaceous tree, Lyonothamnus floribundus, with very hard wood
3. any of various other trees with hard wood, such as the mopani
References in periodicals archive ?
Gary Nabhan, the Museum's former Director of Conservation and Science, worked on the ecology of the desert ironwood tree (see sidebar) and revealed its status as a keystone species upon which numerous other plants and animals depend.
The Arizona Sonora Desert Museum has had a long-standing interest in the wellbeing of the desert ironwood tree.
Ironwood has existing patents and pending patent applications for IW-3718 that are expected to provide patent coverage into the mid-2030s.
At this exciting and transformational time for Ironwood, Chriss collaborative leadership style, dedication to patients and track record of translating science into important therapies for patients will help Ironwood scale our capabilities and enhance the speed, quality, functional integration and innovative means by which we advance our medicines to patients.
Ironwood has built an impressive R&D team with a proven ability to innovate and address patients unmet needs, said Dr.
Ironwood and Allergan are evaluating DR1 in adult patients with IBS-C.
Ironwood and Allergan are evaluating DR2 for the potential to treat patients with disorders where lower abdominal pain is a predominant symptom, such as non-constipated subtypes of IBS.
Ironwood and Allergan expect to launch a 72 mcg dose of linaclotide in early 2017 that, if approved by the Food and Drug Administration (FDA), could increase physician prescribing of LINZESS among the estimated 35 million adult CIC patients.